Arterial spin labelling Scanner- and Patient-Independent Robust diagnostic Evaluation
ASPIRE will create a novel imaging biomarker for dementia for diagnosis support. Signs of Alzheimer’s (AD) will be detectable at early stages before clinical manifestation. The solution is based on the non-invasive magnetic resonance imaging (MRI) technique “Arterial Spin Labelling” (ASL) combined with scanner calibration, physiological atlas comparison, and artificial intelligence (AI)-based diagnostic support. The technique will simplify the diagnostic process, reduce cost and patient risk.
Software Solutions
Provided services of ASPIRE will include medical image data management, image data evaluation as well as study-individual set-ups for clinical trials and diagnosis.
Cloud Application
ASPIRE services will be available on the secure mTRIAL platform as cloud applications, making them easily accessible. The app usage will be possible for advanced users and beginners.
Biomarker
ASPIRE will offer ASL dementia biomarker software for the support and assessment of researchers as well as clinical experts within clinical trials and for diagnosis.
ASL Phantom
To ensure high quality results, inter-scanner comparability, optimized scanner profiles as well as the validity of the ASL biomarker, ASL scanner calibration and services will be performed by leading phantom experts.
Our vision is to provide a cost-efficient diagnostic tool for dementia based on the non-invasive MRI technique Arterial Spin Labeling (ASL), applicable to radiological data acquired worldwide. ASL is readily available as a product sequence on all modern MRI scanners, and patients with memory complaints routinely undergo MRI examination to rule out anatomical abnormalities. Adding ASPIRE to the clinical workflow is thus an economic and easy solution to support early reliable diagnosis of AD.
Our vision is to provide a cost-efficient diagnostic tool for dementia based on the non-invasive MRI technique Arterial Spin Labeling (ASL), applicable to radiological data acquired worldwide. ASL is readily available as a product sequence on all modern MRI scanners, and patients with memory complaints routinely undergo MRI examination to rule out anatomical abnormalities. Adding ASPIRE to the clinical workflow is thus an economic and easy solution to support early reliable diagnosis of AD.
Our vision is to provide a cost-efficient diagnostic tool for dementia based on the non-invasive MRI technique Arterial Spin Labeling (ASL), applicable to radiological data acquired worldwide. ASL is readily available as a product sequence on all modern MRI scanners, and patients with memory complaints routinely undergo MRI examination to rule out anatomical abnormalities. Adding ASPIRE to the clinical workflow is thus an economic and easy solution to support early reliable diagnosis of AD.
Clinical Trial Experts
mediri is an agile pioneer of medical imaging. The company translates current research in imaging and analysis methods into better therapies and greater patient well-being.
Biomarker Experts
VU University Medical Center is the embodiment of distinctive patient care, excellence in higher education, and ground-breaking research.
Phantom Experts
Gold Standard Phantoms is a University College London's Institute of Neurology spinout company which is developing, marketing and selling calibration services for Quantitative Medical Imaging.
Clinical Trial Experts
mediri is an agile pioneer of medical imaging. The company translates current research in imaging and analysis methods into better therapies and greater patient well-being.
Biomarker Experts
VU University Medical Center is the embodiment of distinctive patient care, excellence in higher education, and ground-breaking research.
Phantom Experts
Gold Standard Phantoms is a University College London's Institute of Neurology spinout company which is developing, marketing and selling calibration services for Quantitative Medical Imaging.
Clinical Trial Experts
mediri is an agile pioneer of medical imaging. The company translates current research in imaging and analysis methods into better therapies and greater patient well-being.
Biomarker Experts
VU University Medical Center is the embodiment of distinctive patient care, excellence in higher education, and ground-breaking research.
Phantom Experts
Gold Standard Phantoms is a University College London's Institute of Neurology spinout company which is developing, marketing and selling calibration services for Quantitative Medical Imaging.
Our web-based mTRIAL platform supports all steps of processing medical image data, from acquisition to evaluation and also the collaboration between all stakeholders of a clinical trial. Study data can be transferred, processed and managed via an intuitive user-interface. The modular design guarantees that your individual requirements will be met.
WHITEBOX connects clinics and radiological pratices to a secure platform which allows automated AI-supported analysis of medical image data for diagnosis support. A patent has been filed to protect the inherent data security concept. The development of this innovative product is supported by the German Federal Ministry for Economic Affairs and Energy.
ExploreASL is a pipeline and toolbox for image processing and statistics of arterial spin labeling perfusion MR images. It is designed as a multi-OS, open source, collaborative framework that facilitates cross-pollination between image processing method developers and clinical investigators.
QASPER (Quantitative Arterial Spin Labelling Perfusion Reference) is a calibration and quality assurance standard for MRI perfusion measurements using Arterial Spin Labelling (ASL). It simulates the process of delivery of arterial blood to an organ in a controlled and reproducible manner.
Our web-based mTRIAL platform supports all steps of processing medical image data, from acquisition to evaluation and also the collaboration between all stakeholders of a clinical trial. Study data can be transferred, processed and managed via an intuitive user-interface. The modular design guarantees that your individual requirements will be met.
WHITEBOX connects clinics and radiological pratices to a secure platform which allows automated AI-supported analysis of medical image data for diagnosis support. A patent has been filed to protect the inherent data security concept. The development of this innovative product is supported by the German Federal Ministry for Economic Affairs and Energy.
ExploreASL is a pipeline and toolbox for image processing and statistics of arterial spin labeling perfusion MR images. It is designed as a multi-OS, open source, collaborative framework that facilitates cross-pollination between image processing method developers and clinical investigators.
QASPER (Quantitative Arterial Spin Labelling Perfusion Reference) is a calibration and quality assurance standard for MRI perfusion measurements using Arterial Spin Labelling (ASL). It simulates the process of delivery of arterial blood to an organ in a controlled and reproducible manner.
Our web-based mTRIAL platform supports all steps of processing medical image data, from acquisition to evaluation and also the collaboration between all stakeholders of a clinical trial. Study data can be transferred, processed and managed via an intuitive user-interface. The modular design guarantees that your individual requirements will be met.
WHITEBOX connects clinics and radiological pratices to a secure platform which allows automated AI-supported analysis of medical image data for diagnosis support. A patent has been filed to protect the inherent data security concept. The development of this innovative product is supported by the German Federal Ministry for Economic Affairs and Energy.
ExploreASL is a pipeline and toolbox for image processing and statistics of arterial spin labeling perfusion MR images. It is designed as a multi-OS, open source, collaborative framework that facilitates cross-pollination between image processing method developers and clinical investigators.
QASPER (Quantitative Arterial Spin Labelling Perfusion Reference) is a calibration and quality assurance standard for MRI perfusion measurements using Arterial Spin Labelling (ASL). It simulates the process of delivery of arterial blood to an organ in a controlled and reproducible manner.
© 2020 Wirtschaft digital Baden-Württemberg
We have been working on improving all technical aspects of ASL for many years, and all team members share the vision to make this a standard diagnostic tool. The idea for ASPIRE was born, to make this a reality for Alzheimer diagnosis support: a highly relevant indication, where ASL can really make a difference.
Dr. Johannes Gregori, Managing Director mediri GmbH, consortium lead
© 2020 Wirtschaft digital Baden-Württemberg
We have been working on improving all technical aspects of ASL for many years, and all team members share the vision to make this a standard diagnostic tool. The idea for ASPIRE was born, to make this a reality for Alzheimer diagnosis support: a highly relevant indication, where ASL can really make a difference.
Dr. Johannes Gregori, Managing Director mediri GmbH, consortium lead
© 2020 Wirtschaft digital Baden-Württemberg
We have been working on improving all technical aspects of ASL for many years, and all team members share the vision to make this a standard diagnostic tool. The idea for ASPIRE was born, to make this a reality for Alzheimer diagnosis support: a highly relevant indication, where ASL can really make a difference.
Dr. Johannes Gregori, Managing Director mediri GmbH, consortium lead
Matthias is a Professor for MR-Physics at the University of Bremen. He is the current CEO of the mediri GmbH, and contributes over 15 years’ experience of R&D in the field of ASL-MRI.
Publications
Reads
Citations
Xavier is a Professor of MRI Physics at UCL. He is the current CEO of GSP, and contributes over 20 years’ experience of R&D in the field of MRI, from new imaging techniques to the development of contrast agents.
Publications
Reads
Citations
Henk Mutsaerts is a medical doctor with a passion for image processing. His research focuses on the development of arterial spin labeling (ASL) perfusion MRI as clinical biomarker in aging and aging-related disease. His research is stratified in three trajectories: 1) standardization, 2) differentiation and 3) application of ASL as a biomarker of cognitive decline.
Publications
Reads
Citations
Matthias is a Professor for MR-Physics at the University of Bremen. He is the current CEO of the mediri GmbH, and contributes over 15 years’ experience of R&D in the field of ASL-MRI.
Publications
Reads
Citations
Xavier is a Professor of MRI Physics at UCL. He is the current CEO of GSP, and contributes over 20 years’ experience of R&D in the field of MRI, from new imaging techniques to the development of contrast agents.
Publications
Reads
Citations
Henk Mutsaerts is a medical doctor with a passion for image processing. His research focuses on the development of arterial spin labeling (ASL) perfusion MRI as clinical biomarker in aging and aging-related disease. His research is stratified in three trajectories: 1) standardization, 2) differentiation and 3) application of ASL as a biomarker of cognitive decline.
Publications
Reads
Citations
Matthias is a Professor for MR-Physics at the University of Bremen. He is the current CEO of the mediri GmbH, and contributes over 15 years’ experience of R&D in the field of ASL-MRI.
Publications
Reads
Citations
Xavier is a Professor of MRI Physics at UCL. He is the current CEO of GSP, and contributes over 20 years’ experience of R&D in the field of MRI, from new imaging techniques to the development of contrast agents.
Publications
Reads
Citations
Henk Mutsaerts is a medical doctor with a passion for image processing. His research focuses on the development of arterial spin labeling (ASL) perfusion MRI as clinical biomarker in aging and aging-related disease. His research is stratified in three trajectories: 1) standardization, 2) differentiation and 3) application of ASL as a biomarker of cognitive decline.
Publications
Reads
Citations
We are proud to announce that one of our research projects was selected for funding within the Europe-wide call EUROSTARS. mediri GmbH is coordinator of the project ASPIRE which will start in May. Within the €2.3 million project we will create a novel imaging biomarker for dementia to support diagnosis together with our strong partners Gold Standard Phantoms and VUmc Amsterdam. Within ASPIRE, we will establish a solution to detect signs of Alzheimer’s disease at early stages before clinical manifestation. We will use Arterial Spin Labelling (ASL) combined with scanner calibration, physiological atlas comparison, and AI-based diagnostic support to simplify the diagnostic process, reduce cost and patient risk.
#dementia #alzheimer #ai #ki #medicalimaging #medicaltechnology #aspiremri
Have a look at this milestone article published in Neuroimage describing the ExploreASL pipeline which allows to analyse ASL images across vendors and platforms. Authors are, amongst others, our CEO Matthias Guenther and our ASPIRE project partners Henk(-Jan) Mutsaerts and Xavier Golay.
For those who speak Dutch, how cool, how honored am I and grateful to my colleagues!
Twee subsidies voor minder belastende MRI-methode om diagnose dementie vroegtijdig te stellen.
The ASPIRE (Arterial spin labeling Scanner- and Patient-Independent Robust Evaluation) consortium aims to facilitate brain perfusion imaging by MRI for dementia diagnosis and prognosis in clinical pharmaceutical studies and clinical practice.
They combine the industry's latest advances to provide a robust, non-invasive imaging technique for AD prediction, seamlessly integrated into the standard MRI examination routine. Artificial intelligence (AI) methods will be used to analyze localized disease-specific changes in brain perfusion for diagnosis support. Amsterdam UMC (location VUmc), with Professor Frederik Barkhof and clinical researcher Henk(-Jan) Mutsaerts, leads the development of the advanced ASL analysis software ExploreASL.
#aspiremri academia-and-industry-join-forces-to-establish-non-invasive-perfusion-mri
We are proud to announce that one of our research projects was selected for funding within the Europe-wide call EUROSTARS. mediri GmbH is coordinator of the project ASPIRE which will start in May. Within the €2.3 million project we will create a novel imaging biomarker for dementia to support diagnosis together with our strong partners Gold Standard Phantoms and VUmc Amsterdam. Within ASPIRE, we will establish a solution to detect signs of Alzheimer’s disease at early stages before clinical manifestation. We will use Arterial Spin Labelling (ASL) combined with scanner calibration, physiological atlas comparison, and AI-based diagnostic support to simplify the diagnostic process, reduce cost and patient risk.
#dementia #alzheimer #ai #ki #medicalimaging #medicaltechnology #aspiremri
Have a look at this milestone article published in Neuroimage describing the ExploreASL pipeline which allows to analyse ASL images across vendors and platforms. Authors are, amongst others, our CEO Matthias Guenther and our ASPIRE project partners Henk(-Jan) Mutsaerts and Xavier Golay.
For those who speak Dutch, how cool, how honored am I and grateful to my colleagues!
Twee subsidies voor minder belastende MRI-methode om diagnose dementie vroegtijdig te stellen.
The ASPIRE (Arterial spin labeling Scanner- and Patient-Independent Robust Evaluation) consortium aims to facilitate brain perfusion imaging by MRI for dementia diagnosis and prognosis in clinical pharmaceutical studies and clinical practice.
They combine the industry's latest advances to provide a robust, non-invasive imaging technique for AD prediction, seamlessly integrated into the standard MRI examination routine. Artificial intelligence (AI) methods will be used to analyze localized disease-specific changes in brain perfusion for diagnosis support. Amsterdam UMC (location VUmc), with Professor Frederik Barkhof and clinical researcher Henk(-Jan) Mutsaerts, leads the development of the advanced ASL analysis software ExploreASL.
#aspiremri academia-and-industry-join-forces-to-establish-non-invasive-perfusion-mri
We are proud to announce that one of our research projects was selected for funding within the Europe-wide call EUROSTARS. mediri GmbH is coordinator of the project ASPIRE which will start in May. Within the €2.3 million project we will create a novel imaging biomarker for dementia to support diagnosis together with our strong partners Gold Standard Phantoms and VUmc Amsterdam. Within ASPIRE, we will establish a solution to detect signs of Alzheimer’s disease at early stages before clinical manifestation. We will use Arterial Spin Labelling (ASL) combined with scanner calibration, physiological atlas comparison, and AI-based diagnostic support to simplify the diagnostic process, reduce cost and patient risk.
#dementia #alzheimer #ai #ki #medicalimaging #medicaltechnology #aspiremri
Have a look at this milestone article published in Neuroimage describing the ExploreASL pipeline which allows to analyse ASL images across vendors and platforms. Authors are, amongst others, our CEO Matthias Guenther and our ASPIRE project partners Henk(-Jan) Mutsaerts and Xavier Golay.
For those who speak Dutch, how cool, how honored am I and grateful to my colleagues!
Twee subsidies voor minder belastende MRI-methode om diagnose dementie vroegtijdig te stellen.
The ASPIRE (Arterial spin labeling Scanner- and Patient-Independent Robust Evaluation) consortium aims to facilitate brain perfusion imaging by MRI for dementia diagnosis and prognosis in clinical pharmaceutical studies and clinical practice.
They combine the industry's latest advances to provide a robust, non-invasive imaging technique for AD prediction, seamlessly integrated into the standard MRI examination routine. Artificial intelligence (AI) methods will be used to analyze localized disease-specific changes in brain perfusion for diagnosis support. Amsterdam UMC (location VUmc), with Professor Frederik Barkhof and clinical researcher Henk(-Jan) Mutsaerts, leads the development of the advanced ASL analysis software ExploreASL.
#aspiremri academia-and-industry-join-forces-to-establish-non-invasive-perfusion-mri
Lets get in touch. Send us a message:
Heidelberg, Germany
Phone: +49 6221 725 6970
Amsterdam, Netherlands
London, UK
The aspire-mri.eu website is provided by the mediri GmbH, Am Taubenfeld 21/1, 69123 Heidelberg, Germany. CEO: Prof. Dr. M. Günther, COO: Dr. J. Müller. Registry court: Amtsgericht Mannheim, HRB 337863. UStID-Nr. DE 238569040.
Feel free to contact our general ASPIRE team using ASPIRE@mediri.com or message an individual ASPIRE project partner using one of the contact forms above.
The Eurostars-Project ASPIRE 01QE2026A is funded by the Federal Ministry of Education and Research, the Eurostars program as well as Innovate UK.
The aspire-mri.eu website is provided by the mediri GmbH, Am Taubenfeld 21/1, 69123 Heidelberg, Germany. CEO: Prof. Dr. M. Günther, COO: Dr. J. Müller. Registry court: Amtsgericht Mannheim, HRB 337863. UStID-Nr. DE 238569040.
Feel free to contact our general ASPIRE team using ASPIRE@mediri.com or message an individual ASPIRE project partner using one of the contact forms above.
The Eurostars-Project ASPIRE 01QE2026A is funded by the Federal Ministry of Education and Research, the Eurostars program as well as Innovate UK.
Sponsored by ...
Regarding our terms of use and the ASPIRE privacy policy, please checkout the fields below or contact our team.
Regarding our terms of use and the ASPIRE privacy policy, please checkout the fields below or contact our team.
This website is provided as a courtesy of the ASPIRE consortium. While we have endeavoured to provide helpful information, nothing herein is intended as an offer for sale, representation, or warranty unless otherwise noted. If you believe that you may be interested in our products or services, or in knowing more about us, please do not hesitate to contact us.
The information on this web site is provided “as is”, without warranty of any kind, either express or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Some jurisdictions do not allow the exclusion of implied warranties, so that particular exclusion may not apply to you.
In no event shall the ASPIRE consortium be liable for any damages whatsoever, including, without limitation, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the use or reliance on this web site or the information contained in it. This shall apply whether such damages arise (or are alleged to arise) in contract, negligence, tort, under statute, in equity, at law or otherwise.
We shall not be liable for any errors or omissions contained on this web site, and reserve the right to make changes without notice. Again, all information is provided “AS IS.”
We make no representations whatsoever about any other web site which you may access through this one. When you access a non-ASPIRE web site, please understand that it is independent from us, and that we have no control over the content on that web site. In addition, a link to a non-ASPIRE web site does not mean that we endorse or accept any responsibility for the content, or the use, of such website.
This website, including layout and graphics, is a copyrighted work and is protected by worldwide copyright laws and treaties. You may not repost or reproduce this work, prepare derivative works based on this work, distribute copies of this work to the public by sale or other transfer of ownership, or by rental, lease or lending, perform or display this work publicly, or otherwise commercially exploit this work. However, you may view, download, and reprint copies of the work provided that (a) a notice in the form:
“Copyright © 2020 by ASPIRE consortium. A project co-founded by the German Federal Ministry of Education and Research, EUREKA member countries, and the European Union Horizon 2020 Framework Programme, called “Arterial spin labelling Scanner- and Patient-Independent Robust diagnostic Evaluation” under the contract number 01QE2026A. All rights reserved.”
appears in all copies, (b) use of copies is for informational, non-commercial, and personal use only and is not be copied or posted on any network computer or broadcast in any media, (c) no modifications are made to the copied work. If you wish to make more extensive or other uses of this work (or portions thereof), you must have our express written permission. Please contact us if you wish to pursue this further.
Note that any product, process, or technology described on this website may be the subject of other Intellectual Property rights reserved by the members of the ASPIRE consortium and are not licensed hereunder. Except as expressly provided herein, we do not grant to you by virtue of this website or the statements contained herein any express or implied right under any of those Intellectual Property rights.
We take the protection of personal data very seriously. Protecting your privacy is extremely important to us, which is why compliance with the provisions of the Federal Data Protection Act is a matter of course for us.
Using our website is usually possible without providing personal data. If personal data (for example name, address or e-mail addresses) is collected on our website, this is always done on a voluntary basis. As a responsible consortium, we do not use automatic decision-making or profiling.
Please always consider that data transmission on the Internet (e.g. when communicating via e-mail) can have security gaps. Seamless protection of data from access by third-parties is not possible. Our website data is stored on servers hosted by GitHub, based on a dedicated agreement on data processing.
We automatically collect and store information in so-called server log files, which your browser automatically transmits. These are:
This data is not merged with other data sources. We reserve the right to examine the data subsequently, if we have concrete indications of illegal use.
The website aspire-mri.eu and its subpages are not using cookies.
Users of this website may contact us via e-mail. If you choose to send us your personal data, we will only use that data to respond to your message. Beyond that purpose, we will neither collect personal data nor create individual profiles, e.g. for advertising or marketing.
When you contact us, any personal data you provide is voluntary. Please do not include sensitive personal data or other sensitive information in the content of your e-mail. If you wish to send us confidential information, please contact us for information about encrypted communication channels.
You have the right at any time to receive information at no charge concerning your stored personal data, the origin and recipients of your personal data, and the purpose for which your personal data is processed, as well as a right to have your personal data corrected, blocked, or deleted. In this regard, or if you have questions concerning personal data, you can contact us at any time via ASPIRE@mediri.com or our general contact information.
In addition, you have a right of appeal to the data protection supervisory authority. This is:
Die Bundesbeauftragte für den Datenschutz und die Informationsfreiheit
Husarenstr. 30,
53117 Bonn,
Germany
We may make changes to this privacy policy from time to time. If we change our privacy policy, we will post the changes on this page.
If you have questions about this privacy policy, please email us at ASPIRE@mediri.com.